Gilead Sciences, Inc. (GILD) Given Consensus Rating of “Buy” by Brokerages
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have earned a consensus recommendation of “Buy” from the thirty-two analysts that are covering the firm, MarketBeat reports. Eleven research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $84.15.
Several brokerages have recently weighed in on GILD. Jefferies Group LLC reissued a “hold” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 11th. BMO Capital Markets reissued an “outperform” rating and issued a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Robert W. Baird reissued an “outperform” rating and issued a $87.00 target price on shares of Gilead Sciences in a research note on Thursday, July 13th. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Finally, Leerink Swann reissued a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, June 22nd.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP James R. Meyers sold 60,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $83.19, for a total transaction of $4,991,400.00. Following the sale, the executive vice president now owns 62,715 shares of the company’s stock, valued at $5,217,260.85. The disclosure for this sale can be found here. Insiders sold a total of 466,819 shares of company stock valued at $36,740,240 over the last quarter. 1.30% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in GILD. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 1,400 shares during the period. Dubuque Bank & Trust Co. lifted its stake in Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 267 shares during the period. Penserra Capital Management LLC lifted its stake in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 144 shares during the period. Webster Bank N. A. lifted its stake in Gilead Sciences by 51.7% during the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 624 shares during the period. Finally, American Beacon Advisors Inc. acquired a new stake in Gilead Sciences during the 1st quarter valued at approximately $143,000. Institutional investors and hedge funds own 73.97% of the company’s stock.
Gilead Sciences (NASDAQ GILD) traded up 0.79% during trading on Friday, hitting $83.27. 5,654,657 shares of the company’s stock were exchanged. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a market cap of $108.74 billion, a price-to-earnings ratio of 9.04 and a beta of 1.19. The firm has a 50 day moving average price of $77.54 and a 200 day moving average price of $70.38.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the prior year, the firm posted $3.08 earnings per share. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, equities research analysts predict that Gilead Sciences will post $8.78 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.50%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
WARNING: This article was reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/09/23/gilead-sciences-inc-gild-given-consensus-rating-of-buy-by-brokerages.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.